Literature DB >> 12361401

Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.

J Rivier1, J Gulyas, D Kirby, W Low, M H Perrin, K Kunitake, M DiGruccio, J Vaughan, J C Reubi, B Waser, S C Koerber, V Martinez, L Wang, Y Taché, W Vale.   

Abstract

We present evidence that members of the corticotropin releasing factor (CRF) family assume distinct structures when interacting with the CRF(1) and CRF(2) receptors. Predictive methods, physicochemical measurements, and structure-activity relationship studies have suggested that CRF, its family members, and competitive antagonists such as astressin [cyclo(30-33)[DPhe(12),Nle(21),Glu(30),Lys(33),Nle(38)]hCRF((12-41))] assume an alpha-helical conformation when interacting with their receptors. We had shown that alpha-helical CRF((9-41)) and sauvagine showed some selectivity for CRF receptors other than that responsible for ACTH secretion(1) and later for CRF2.(2) More recently, we suggested the possibility of a helix-turn-helix motif around a turn encompassing residues 30-33(3) that would confer high affinity for both CRF(1) and CRF(2)(2,4) in agonists and antagonists of all members of the CRF family.(3) On the other hand, the substitutions that conferred ca. 100-fold CRF(2) selectivity to the antagonist antisauvagine-30 [[DPhe(11),His(12)]sauvagine((11-40))] did not confer such property to the corresponding N-terminally extended agonists. We find here that a Glu(32)-Lys(35) side chain to side chain covalent lactam constraint in hCRF and the corresponding Glu(31)-Lys(34) side chain to side chain covalent lactam constraint in sauvagine yield potent ligands that are selective for CRF(2). Additionally, we introduced deletions and substitutions known to increase duration of action to yield antagonists such as cyclo(31-34)[DPhe(11),His(12),C(alpha)MeLeu(13,39),Nle(17),Glu(31),Lys(34)]Ac-sauvagine((8-40)) (astressin(2)-B) with CRF(2) selectivities greater than 100-fold. CRF receptor autoradiography was performed in rat tissue known to express CRF(2) and CRF(1) in order to confirm that astressin(2)-B could indeed bind to established CRF(2) but not CRF(1) receptor-expressing tissues. Extended duration of action of astressin(2)-B vs that of antisauvagine-30 is demonstrated in the CRF(2)-mediated animal model whereby the inhibition of gastric emptying of a solid meal in mice by urocortin administered intraperitoneally at time zero is antagonized by the administration of astressin(2)-B but not by antisauvagine-30 at times -3 and -6 h while both peptides are effective when given 10 min before urocortin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361401     DOI: 10.1021/jm0202122

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  68 in total

1.  Activation of corticotropin-releasing factor receptor 2 mediates the colonic motor coping response to acute stress in rodents.

Authors:  Guillaume Gourcerol; S Vincent Wu; Pu-Qing Yuan; Hung Pham; Marcel Miampamba; Muriel Larauche; Paul Sanders; Tomofumi Amano; Agata Mulak; Eunok Im; Charalabos Pothoulakis; Jean Rivier; Yvette Taché; Mulugeta Million
Journal:  Gastroenterology       Date:  2011-01-26       Impact factor: 22.682

2.  Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).

Authors:  Judit Erchegyi; Lixin Wang; Jozsef Gulyas; Manoj Samant; Marilyn H Perrin; Kathy Lewis; Charleen Miller; Joan Vaughan; Cynthia Donaldson; Wolfgang Fischer; William Low; Seiichi Yakabi; Hiroshi Karasawa; Yvette Taché; Catherine Rivier; Jean Rivier
Journal:  J Med Chem       Date:  2016-02-03       Impact factor: 7.446

3.  Involvement of mTOR in Type 2 CRF Receptor Inhibition of Insulin Signaling in Muscle Cells.

Authors:  Hongxia Chao; Haochen Li; Rebecca Grande; Vitor Lira; Zhen Yan; Thurl E Harris; Chien Li
Journal:  Mol Endocrinol       Date:  2015-04-15

Review 4.  Corticotropin-releasing factor receptors and stress-related alterations of gut motor function.

Authors:  Yvette Taché; Bruno Bonaz
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

5.  Role of the corticotropin-releasing factor receptor type 2 in the control of food intake in mice: a meal pattern analysis.

Authors:  A Tabarin; Y Diz-Chaves; D Consoli; M Monsaingeon; T L Bale; M D Culler; R Datta; F Drago; W W Vale; G F Koob; E P Zorrilla; A Contarino
Journal:  Eur J Neurosci       Date:  2007-10       Impact factor: 3.386

Review 6.  Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction.

Authors:  Dimitris K Grammatopoulos
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

7.  Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval.

Authors:  Eva M Fekete; Koki Inoue; Yu Zhao; Jean E Rivier; Wylie W Vale; Attila Szücs; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2006-10-04       Impact factor: 7.853

Review 8.  Synaptic physiology of central CRH system.

Authors:  Joel P Gallagher; Luis F Orozco-Cabal; Jie Liu; Patricia Shinnick-Gallagher
Journal:  Eur J Pharmacol       Date:  2008-02-01       Impact factor: 4.432

9.  Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse.

Authors:  Adrie W Bruijnzeel; Melissa Prado; Shani Isaac
Journal:  Biol Psychiatry       Date:  2009-02-12       Impact factor: 13.382

Review 10.  CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome.

Authors:  Y Taché; V Martinez; L Wang; M Million
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.